(Reuters) – Colchicine, a commonly used anti-inflammatory drug, will be investigated as a possible treatment for COVID-19 in the Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial, the study website posted on Friday.
The RECOVERY trial, which is the world’s largest clinical trial of treatments for patients hospitalised with COVID-19, will randomly allocate at least 2,500 patients recruited to receive colchicine.
(Reporting by Muvija M in Bengaluru; Editing by David Goodman)
